MD - Earnings announcements

Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2026 first quarter, Pediatrix reported the following results: Net revenue of $476 million; Net income of $30 million; and Adjusted EBITDA of $58 million. "Our first quarter operating results exceeded our expectations, driven by top-line growth," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "Our priorities for 2026 remain focused on maximizing quality driven support for our hospital partners. With robust cash flow a

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 5, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2026. A detailed press release will be issued the morning of May 5, 2026 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. About Pediatrix Medical Group Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children acr

Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.40 per share for the three months ended December 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.50. For the 2025 fourth quarter, Pediatrix reported the following results: Net revenue of $494 million; Net income of $34 million; and Adjusted EBITDA of $66 million. "Our fourth quarter operating results were in line with our revised upward expectations and reflected solid same-unit revenue growth, partially offset by an increase in variable practice incentive compensation," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "Ou

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 19, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2025. A detailed press release will be issued the morning of February 19, 2026 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies

Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.84 per share for the three months ended September 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.67. For the 2025 third quarter, Pediatrix reported the following results: Net revenue of $493 million; Net income of $72 million; and Adjusted EBITDA of $87 million. "Our operating results for the third quarter exceeded our expectations and were driven by a combination of reimbursement-related factors, including strong collection activity, higher patient acuity and slightly favorable payor mix, a

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Monday, November 3, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2025. A detailed press release will be issued the morning of November 3, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and

Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.46 per share for the three months ended June 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.53. For the 2025 second quarter, Pediatrix reported the following results: Net revenue of $469 million; Net income of $39 million; and Adjusted EBITDA of $73 million. "Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 5, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2025. A detailed press release will be issued the morning of August 5, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre

Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across

Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 20, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2024. A detailed press release will be issued the morning of February 20, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies

Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch

Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 6, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2024. A detailed press release will be issued the morning of August 6, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings of $0.05 per share for the three months ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: Net revenue of $495 million; Net income of $4 million; and Adjusted EBITDA of $37 million. "Our first quarter operating results were in line with our expectations," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our key priorities for 2024 are sharply focused on operating efficiency and stabiliz

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2024. A detailed press release will be issued the morning of May 7, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and c

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $1.50 per share for the three months ended December 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.32. For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: Net revenue of $496 million; Loss from continuing operations of $124 million; and Adjusted EBITDA of $51 million. "Our fourth quarter operating results were consistent with our expectations," said James D. Swift, M.D., Chief Executive Officer of

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, February 20, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2023. A detailed press release will be issued the morning of February 20, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to wome

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.26 per share for the three months ended September 30, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.32. For the 2023 third quarter, Pediatrix reported the following results from continuing operations: Net revenue of $507 million; Income from continuing operations of $21 million; and Adjusted EBITDA of $50 million. "We believe the underlying fundamentals of our business remain strong, however, the third quarter was more challenged than expect

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, November 2, 2023 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2023. A detailed press release will be issued the morning of November 2, 2023 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to wome

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.34 per share for the three months ended June 30, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: Net revenue of $501 million; Income from continuing operations of $28 million; and Adjusted EBITDA of $59 million. "Our second quarter operating results were in line with our expectations and reflect stable patient volumes and strong cash generatio

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, August 3, 2023 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2023. A detailed press release will be issued the morning of August 3, 2023 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: Net revenue of $491 million; Income from continuing operations of $14 million; and Adjusted EBITDA of $40 million. "Our first quarter operating results were in line with our expectations and reflected modest improvements in revenue cycle management

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 2, 2023 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2023. A detailed press release will be issued the morning of May 2, 2023 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and c

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.29 per share for the three months ended December 31, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.47. For the 2022 fourth quarter, Pediatrix reported the following results from continuing operations: Net revenue of $514 million; Income from continuing operations of $36 million; and Adjusted EBITDA of $66 million. "Our fourth quarter operating results reflected solid patient volumes, stable payor mix, and reduced overhead, counterbalanced by cont

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, February 17, 2023 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2022. A detailed press release will be issued the morning of February 17, 2023 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, b

Pediatrix Medical Group, Inc. (NYSE:MD) today announced that it will present on Tuesday, November 8, 2022 at 3:15 p.m. PT to investors attending the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California. The presentation will be broadcast through live audio webcasts. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children acro

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.35 per share for the three months ended September 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.40. For the 2022 third quarter, Pediatrix reported the following results from continuing operations: Net revenue of $490 million; Income from continuing operations of $29 million; and Adjusted EBITDA of $58 million. "We are disappointed in our third-quarter operating results, which reflected operational challenges in billing and collections and mod

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, November 3, 2022 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2022. A detailed press release will be issued the morning of November 3, 2022 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women,

Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.47. For the 2022 second quarter, Pediatrix reported the following results from continuing operations: Net revenue of $486 million; Income from continuing operations of $31 million; and Adjusted EBITDA of $66 million. "Our bottom line results reflected modest volume growth and continued operating efficiency," said Mark S. Ordan, Chief Executive Officer o

Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, August 4, 2022 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2022. A detailed press release will be issued the morning of August 4, 2022 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies an

Mednax, Inc. (NYSE:MD), whose affiliated practices operate as Pediatrix® Medical Group, the nation's leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $0.25 per share for the three months ended March 31, 2022. Results from continuing operations include a pretax loss on early extinguishment of debt of $57 million. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.33. For the 2022 first quarter, Mednax reported the following results from continuing operations: Net revenue of $482 million; Loss from continuing operations of $21 million; and Adjusted EBITDA of $51 million

Mednax, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, April 28, 2022 at 9:00 a.m. ET, to discuss results from operations for the quarter ended March 31, 2022. A detailed press release will be issued the morning of April 28, 2022 before the securities markets open. The investor conference call will be webcast and can be accessed at Mednax's website, www.mednax.com/investors. ABOUT MEDNAX Mednax, Inc. is a national medical group comprised of the nation's leading providers of physician services practicing under the Pediatrix® brand. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women

Mednax, Inc. (NYSE:MD), and its affiliated practices operating as Pediatrix® Medical Group, the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.47 per share for the three months ended December 31, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.52. For the 2021 fourth quarter, Mednax reported the following results from continuing operations: Net revenue of $499 million; Income from continuing operations of $68 million; and Adjusted EBITDA of $81 million. "Our fourth quarter results mark the end of a solid year, thanks to our focus on women's,

Mednax, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 17, 2022 at 9:00 a.m. ET, to discuss results from operations for the quarter and the year ended December 31, 2021. A detailed press release will be issued the morning of February 17, 2022 before the securities markets open. The investor conference call will be webcast and can be accessed at Mednax's website, www.mednax.com/investors. ABOUT MEDNAX Mednax, Inc. is a national medical group comprised of the nation's leading providers of physician services practicing under the Pediatrix® brand. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excel

Mednax, Inc. (NYSE:MD), the national medical group specializing in prenatal, neonatal, and pediatric services, today reported earnings from continuing operations of $0.37 per share for the three months ended September 30, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.46. For the 2021 third quarter, Mednax reported the following results from continuing operations: Net revenue of $493 million; Income from continuing operations of $32 million; and Adjusted EBITDA of $73 million. "We are pleased with our third-quarter results, the strategic steps we have been taking, and the strength of our balance sheet," said Mark S. Ordan, Chief Executive O

Mednax, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, October 28, 2021 at 9:00 a.m. ET, to discuss results from operations for the quarter and nine months ended September 30, 2021. A detailed press release will be issued the morning of October 28, 2021 before the securities markets open. The investor conference call will be webcast and can be accessed at Mednax's website, www.mednax.com/investors. ABOUT MEDNAX Mednax, Inc. is a national medical group comprised of the nation's leading providers of physician services. Physicians and advanced practitioners practicing as part of Mednax's Pediatrix and Obstetrix Medical Groups are reshaping the delivery of care

Mednax, Inc. (NYSE:MD), the national medical group specializing in prenatal, neonatal, and pediatric services, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.41. For the 2021 second quarter, Mednax reported the following results from continuing operations: Net revenue of $473 million; Income from continuing operations of $31 million; and Adjusted EBITDA of $66 million. "Strong patient volume trends across the spectrum of our service lines provided the foundation for strong second quarter results," said Mark S. Ordan, Chief Executive Off